![Page 1: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris](https://reader036.vdocument.in/reader036/viewer/2022062322/5697bf7a1a28abf838c82c03/html5/thumbnails/1.jpg)
Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer
Presented By Boris Winterhoff at 2014 ASCO Annual Meeting
![Page 2: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris](https://reader036.vdocument.in/reader036/viewer/2022062322/5697bf7a1a28abf838c82c03/html5/thumbnails/2.jpg)
Disclosure
Presented By Boris Winterhoff at 2014 ASCO Annual Meeting
![Page 3: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris](https://reader036.vdocument.in/reader036/viewer/2022062322/5697bf7a1a28abf838c82c03/html5/thumbnails/3.jpg)
Slide 3
Presented By Boris Winterhoff at 2014 ASCO Annual Meeting
![Page 4: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris](https://reader036.vdocument.in/reader036/viewer/2022062322/5697bf7a1a28abf838c82c03/html5/thumbnails/4.jpg)
ICON7/AGO-OVAR 11
Presented By Boris Winterhoff at 2014 ASCO Annual Meeting
![Page 5: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris](https://reader036.vdocument.in/reader036/viewer/2022062322/5697bf7a1a28abf838c82c03/html5/thumbnails/5.jpg)
ICON7/AGO-OVAR 11 <br />PFS and OS
Presented By Boris Winterhoff at 2014 ASCO Annual Meeting
![Page 6: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris](https://reader036.vdocument.in/reader036/viewer/2022062322/5697bf7a1a28abf838c82c03/html5/thumbnails/6.jpg)
ICON7/AGO-OVAR 11 <br />PFS and OS<br />High risk group suboptimal stage III and stage IV
Presented By Boris Winterhoff at 2014 ASCO Annual Meeting
![Page 7: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris](https://reader036.vdocument.in/reader036/viewer/2022062322/5697bf7a1a28abf838c82c03/html5/thumbnails/7.jpg)
Molecular Classification of HGS Ovarian Cancer
Presented By Boris Winterhoff at 2014 ASCO Annual Meeting
![Page 8: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris](https://reader036.vdocument.in/reader036/viewer/2022062322/5697bf7a1a28abf838c82c03/html5/thumbnails/8.jpg)
Slide 8
Presented By Boris Winterhoff at 2014 ASCO Annual Meeting
![Page 9: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris](https://reader036.vdocument.in/reader036/viewer/2022062322/5697bf7a1a28abf838c82c03/html5/thumbnails/9.jpg)
Slide 9
Presented By Boris Winterhoff at 2014 ASCO Annual Meeting
![Page 10: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris](https://reader036.vdocument.in/reader036/viewer/2022062322/5697bf7a1a28abf838c82c03/html5/thumbnails/10.jpg)
Slide 10
Presented By Boris Winterhoff at 2014 ASCO Annual Meeting
![Page 11: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris](https://reader036.vdocument.in/reader036/viewer/2022062322/5697bf7a1a28abf838c82c03/html5/thumbnails/11.jpg)
Slide 11
Presented By Boris Winterhoff at 2014 ASCO Annual Meeting
![Page 12: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris](https://reader036.vdocument.in/reader036/viewer/2022062322/5697bf7a1a28abf838c82c03/html5/thumbnails/12.jpg)
Slide 12
Presented By Boris Winterhoff at 2014 ASCO Annual Meeting
![Page 13: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris](https://reader036.vdocument.in/reader036/viewer/2022062322/5697bf7a1a28abf838c82c03/html5/thumbnails/13.jpg)
PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Overall (n=359)
Presented By Boris Winterhoff at 2014 ASCO Annual Meeting
![Page 14: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris](https://reader036.vdocument.in/reader036/viewer/2022062322/5697bf7a1a28abf838c82c03/html5/thumbnails/14.jpg)
PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />High risk for progression (n=119)
Presented By Boris Winterhoff at 2014 ASCO Annual Meeting
![Page 15: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris](https://reader036.vdocument.in/reader036/viewer/2022062322/5697bf7a1a28abf838c82c03/html5/thumbnails/15.jpg)
PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Proliferative Subtype (n=96)
Presented By Boris Winterhoff at 2014 ASCO Annual Meeting
![Page 16: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris](https://reader036.vdocument.in/reader036/viewer/2022062322/5697bf7a1a28abf838c82c03/html5/thumbnails/16.jpg)
PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Mesenchymal Subtype (n=68)
Presented By Boris Winterhoff at 2014 ASCO Annual Meeting
![Page 17: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris](https://reader036.vdocument.in/reader036/viewer/2022062322/5697bf7a1a28abf838c82c03/html5/thumbnails/17.jpg)
PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Differentiated Subtype (n=73)
Presented By Boris Winterhoff at 2014 ASCO Annual Meeting
![Page 18: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris](https://reader036.vdocument.in/reader036/viewer/2022062322/5697bf7a1a28abf838c82c03/html5/thumbnails/18.jpg)
PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Immunoreactive Subtype (n=122)
Presented By Boris Winterhoff at 2014 ASCO Annual Meeting
![Page 19: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris](https://reader036.vdocument.in/reader036/viewer/2022062322/5697bf7a1a28abf838c82c03/html5/thumbnails/19.jpg)
Slide 19
Presented By Boris Winterhoff at 2014 ASCO Annual Meeting
![Page 20: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris](https://reader036.vdocument.in/reader036/viewer/2022062322/5697bf7a1a28abf838c82c03/html5/thumbnails/20.jpg)
PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Proliferative Subtype HGS (n=63)
Presented By Boris Winterhoff at 2014 ASCO Annual Meeting
![Page 21: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris](https://reader036.vdocument.in/reader036/viewer/2022062322/5697bf7a1a28abf838c82c03/html5/thumbnails/21.jpg)
PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Mesenchymal Subtype HGS (n=43)
Presented By Boris Winterhoff at 2014 ASCO Annual Meeting
![Page 22: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris](https://reader036.vdocument.in/reader036/viewer/2022062322/5697bf7a1a28abf838c82c03/html5/thumbnails/22.jpg)
Summary
Presented By Boris Winterhoff at 2014 ASCO Annual Meeting
![Page 23: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris](https://reader036.vdocument.in/reader036/viewer/2022062322/5697bf7a1a28abf838c82c03/html5/thumbnails/23.jpg)
Conclusion
Presented By Boris Winterhoff at 2014 ASCO Annual Meeting
![Page 24: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris](https://reader036.vdocument.in/reader036/viewer/2022062322/5697bf7a1a28abf838c82c03/html5/thumbnails/24.jpg)
Acknowledgements
Presented By Boris Winterhoff at 2014 ASCO Annual Meeting
![Page 25: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris](https://reader036.vdocument.in/reader036/viewer/2022062322/5697bf7a1a28abf838c82c03/html5/thumbnails/25.jpg)
Summary
Presented By Boris Winterhoff at 2014 ASCO Annual Meeting